GO:0120116 glucagon processing: Proglucagon Proteolysis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0120116 (glucagon processing) is the biological process by which the precursor proglucagon is proteolytically cleaved to form mature glucagon.
• Proglucagon is encoded by GCG and is processed in a tissue-specific manner, yielding glucagon in pancreatic alpha cells and glucagon-like peptides (GLP-1, GLP-2, oxyntomodulin) in intestinal L cells.
• The prohormone convertases PC1/3 (PCSK1) and PC2 (PCSK2), together with carboxypeptidase E (CPE), are the principal enzymes that execute proglucagon cleavage.
• Mature glucagon is a 29-amino-acid hormone that counteracts insulin and raises blood glucose; its secretion is regulated by glucose, amino acids, and other nutrients.
• Dysregulation of glucagon processing and secretion contributes to diabetes, glucagonomas, and other metabolic disorders.
• Research on glucagon processing uses CRISPR knockout, point-mutation, knock-in, and overexpression models, combined with proteomics, secretion assays, and bioinformatics.
Description
Glucagon processing (GO:0120116) is the biological process that converts the precursor protein proglucagon into mature glucagon through limited proteolysis. This process is essential for the production of glucagon, a key hormone that opposes insulin action and maintains blood glucose homeostasis. Understanding glucagon processing is fundamental for researchers studying glucose metabolism, pancreatic islet biology, and metabolic diseases such as diabetes. The process is not a simple single cleavage; it involves a series of endoproteolytic and exoproteolytic steps that are tightly regulated and tissue-specific. In pancreatic alpha cells, proglucagon is processed primarily to glucagon, whereas in intestinal L cells the same precursor yields glucagon-like peptide-1 (GLP-1), GLP-2, and oxyntomodulin. This differential processing is directed by the expression of specific prohormone convertases. Because of its central role in metabolism, glucagon processing is a target for therapeutic development and a subject of intense research using modern gene-editing and analytical techniques.
glucagon processing At A Glance
| GO ID | GO:0120116 |
|---|---|
| GO term | glucagon processing |
| Ontology | biological_process |
| Synonym | none |
| Definition | The formation of mature glucagon by proteolysis of the precursor proglucagon. |
| Major function | Production of mature glucagon from proglucagon via proteolytic cleavage. |
| Precursor | Proglucagon (encoded by GCG) |
| Key enzymes | Prohormone convertases PC1/3 (PCSK1), PC2 (PCSK2), carboxypeptidase E (CPE) |
| Primary tissue | Pancreatic alpha cells; also intestinal L cells for GLP-1/GLP-2 |
What Is GO:0120116?
According to the Gene Ontology, glucagon processing (GO:0120116) is defined as the formation of mature glucagon by proteolysis of the precursor proglucagon. In other words, it is the set of proteolytic events that remove intervening sequences from proglucagon to liberate the bioactive glucagon peptide. This definition encompasses the enzymatic cleavages that occur within the secretory pathway of specialized endocrine cells, primarily pancreatic alpha cells.
Why Is glucagon processing Important in Cell Biology?
Glucagon processing is critically important because it generates the hormone glucagon, which is the primary counter-regulatory hormone to insulin and is essential for maintaining blood glucose levels. Dysregulation of glucagon processing or secretion is implicated in diabetes mellitus, where hyperglucagonemia contributes to hyperglycemia. Additionally, understanding this process is vital for interpreting the biology of glucagonomas and other neuroendocrine tumors that may produce glucagon or related peptides. The process also serves as a model for studying prohormone processing in general, with implications for therapeutic development of glucagon-like peptides.
• Glucagon processing produces glucagon, a key hormone that raises blood glucose and opposes insulin.
• Defects in glucagon processing or secretion are linked to diabetes and metabolic dysregulation.
• Tissue-specific processing of proglucagon yields distinct peptides (glucagon vs. GLP-1/GLP-2) with different physiological roles.
• Glucagonomas and other tumors may exhibit altered glucagon processing, affecting diagnosis and treatment.
• Proglucagon-derived peptides are used as therapeutics for diabetes and obesity, highlighting the clinical relevance of processing.
• Studying glucagon processing informs general mechanisms of prohormone convertase function and secretory pathway biology.
• Glucagon deficiency states can cause metabolic disturbances, underscoring the need for proper processing.
• Research on glucagon processing benefits from CRISPR models to dissect gene function.
What Happens During glucagon processing?
Synthesis and translocation of proglucagon
In simple terms: The cell first makes a larger inactive precursor protein called proglucagon.
Proglucagon is synthesized on ribosomes and translocated into the endoplasmic reticulum (ER) of pancreatic alpha cells and intestinal L cells. The precursor contains the sequence of glucagon and additional peptides, and its folding and initial processing begin in the ER. This step is the prerequisite for all subsequent proteolytic events.
Endoproteolytic cleavage by prohormone convertases
In simple terms: Enzymes act like molecular scissors to cut proglucagon at specific sites.
In pancreatic alpha cells, prohormone convertase 2 (PC2, encoded by PCSK2) cleaves proglucagon at dibasic sites to release glucagon and other fragments. In intestinal L cells, prohormone convertase 1/3 (PC1/3, encoded by PCSK1) performs cleavages that yield GLP-1, GLP-2, and oxyntomodulin instead of glucagon. The differential expression of these convertases determines the tissue-specific processing pattern.
Exoproteolytic trimming by carboxypeptidase E
In simple terms: After the initial cuts, another enzyme trims the ends to produce the final hormone.
Following endoproteolytic cleavage, carboxypeptidase E (CPE) removes basic amino acid residues from the C-termini of the intermediate peptides to generate mature glucagon. This exoproteolytic step is essential for producing the bioactive 29-amino-acid glucagon. CPE is widely expressed in neuroendocrine cells and acts on many prohormone intermediates.
Sorting and secretion of mature glucagon
In simple terms: The finished glucagon is packaged and released from the cell when needed.
Mature glucagon is sorted into secretory granules and stored until secretion is triggered. In pancreatic alpha cells, secretion is regulated by glucose, amino acids, and other nutrients, with low glucose stimulating glucagon release. The processed hormone is then secreted into the bloodstream to act on target tissues such as the liver.
Extracellular processing of glucagon to miniglucagon
In simple terms: Sometimes glucagon can be further cut outside the cell to make smaller active fragments.
Beyond intracellular processing, glucagon can undergo extracellular cleavage to produce miniglucagon, a smaller peptide with distinct biological activities. This extracellular processing represents an additional layer of regulation and suggests that glucagon itself can act as a prohormone in certain contexts. Miniglucagon has been reported to modulate cellular functions, although its precise roles are still under investigation.
Key Genes Involved in GO:0120116 glucagon processing
The following genes and proteins are central to glucagon processing, including the precursor, processing enzymes, and regulatory factors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GCG | Encodes proglucagon, the precursor of glucagon and related peptides | Target for knockout/knock-in to study processing and function |
| PCSK1 | Encodes prohormone convertase 1/3 (PC1/3), which processes proglucagon in intestinal L cells | Knockout models reveal tissue-specific processing and GLP-1 production |
| PCSK2 | Encodes prohormone convertase 2 (PC2), which processes proglucagon in pancreatic alpha cells | Knockout models show loss of glucagon production |
| CPE | Encodes carboxypeptidase E, which trims basic residues from processing intermediates | Mutations cause processing defects and endocrine disorders |
| GPR119 | Receptor involved in nutrient sensing and incretin secretion | May influence proglucagon processing indirectly |
| PCSK1N | Encodes proSAAS, an endogenous inhibitor of PC1/3 | Regulates convertase activity and processing |
| PAM | Peptidylglycine alpha-amidating monooxygenase, may modify peptides | Potential role in amidation of glucagon-like peptides |
| SLC30A8 | Zinc transporter affecting granule zinc content and hormone processing | Associated with diabetes risk and alpha cell function |
| GCGR | Glucagon receptor, mediates glucagon action | Knockout models show effects on glucose homeostasis |
| GLP1R | GLP-1 receptor, mediates incretin effects | Relevant for intestinal processing products |
| GLP2R | GLP-2 receptor, mediates intestinal growth effects | Relevant for proglucagon-derived peptides |
| DPP4 | Dipeptidyl peptidase-4, degrades GLP-1 and glucagon | Influences peptide stability and processing outcomes |
| FOXA2 | Transcription factor regulating GCG expression | Knockout affects alpha cell development and glucagon production |
| MAFA | Transcription factor in alpha cells | May regulate GCG transcription and processing |
| PAX6 | Transcription factor important for islet cell development | Mutations affect alpha cell differentiation |
| NEUROD1 | Transcription factor regulating endocrine cell fate | Knockout leads to alpha cell dysfunction |
| ISL1 | Transcription factor for islet cell development | Essential for alpha cell formation |
| CREB | Transcription factor mediating cAMP signaling | Regulates GCG expression and secretion |
How Is glucagon processing Regulated?
Glucagon processing is regulated at multiple levels. Transcription of GCG is controlled by transcription factors such as FOXA2, PAX6, and CREB, which respond to metabolic signals. The expression and activity of prohormone convertases PC1/3 and PC2 are regulated by developmental and metabolic cues, determining the tissue-specific processing pattern. Additionally, the secretory pathway environment, including pH and calcium levels, influences convertase activity. Extracellular processing of glucagon to miniglucagon can be modulated by circulating proteases. Overall, the regulation ensures that mature glucagon is produced appropriately in response to physiological demands.
glucagon processing and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GCG | Glucagon deficiency, hypoglycemia | Knockout mouse or cell line to study processing and secretion |
| PCSK1 | Proprotein convertase 1/3 deficiency, obesity, malabsorptive diarrhea | Patient-derived iPSCs or knockout models |
| PCSK2 | Defects in glucagon processing, alpha cell dysfunction | Knockout cell lines and mouse models |
| CPE | Carboxypeptidase E deficiency, neuroendocrine disorders | Knockout mice and cell-based assays |
| GCGR | Glucagon receptor mutations, diabetes | Knockout and knock-in models to study receptor function |
Diabetes mellitus and glucagon dysregulation
In diabetes, alpha cell dysfunction leads to inappropriate glucagon secretion, contributing to hyperglycemia. Although the processing of proglucagon to glucagon is generally intact, the regulation of secretion is impaired. Studies in animal models and humans have shown that glucagon levels are elevated in diabetes, making glucagon processing and secretion important therapeutic targets.
Glucagonomas and neuroendocrine tumors
Glucagonomas are rare pancreatic neuroendocrine tumors that may produce glucagon or aberrantly processed proglucagon-derived peptides. Not all glucagonomas produce mature glucagon, and some may secrete incompletely processed precursors, leading to diagnostic challenges. Understanding glucagon processing is therefore relevant for tumor biology and biomarker development.
Glucagon deficiency and metabolic disorders
Glucagon deficiency, whether due to genetic defects in processing enzymes or alpha cell loss, can cause hypoglycemia and metabolic disturbances. Mouse models with disrupted glucagon processing have provided insights into the physiological roles of glucagon and related peptides. This highlights the importance of proper processing for glucose homeostasis.
From glucagon processing-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the role of PC2 in glucagon processing? | PCSK2 knockout in pancreatic alpha cell lines (e.g., InR1G9) |
| How does PC1/3 deficiency affect proglucagon processing? | PCSK1 knockout in intestinal L cells or iPSCs |
| Does a specific point mutation in GCG alter processing? | Point-mutation knock-in in GCG using CRISPR |
| Can we track proglucagon processing in live cells? | Tagged knock-in of GCG with fluorescent protein |
| What is the effect of CPE overexpression on glucagon production? | Overexpression of CPE in alpha cell lines |
| How does glucagon receptor signaling feedback on processing? | GCGR knockout or overexpression models |
How to Study the glucagon processing Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mass spectrometry | Peptide masses and sequences | Identification of proglucagon processing products |
| ELISA | Concentration of mature glucagon | Quantification of secretion from cells |
| Western blot | Protein levels of proglucagon and processing enzymes | Validation of knockout or overexpression |
| RT-qPCR | mRNA levels of GCG, PCSK1, PCSK2, CPE | Gene expression analysis |
| Immunofluorescence | Cellular localization of glucagon and enzymes | Tissue and cell imaging |
| CRISPR screening | Identification of genes affecting glucagon processing | Functional genomics |
| Bioinformatics | Pathway and network analysis | Integration of omics data |
Proteomic and peptidomic analysis
Mass spectrometry-based proteomics and peptidomics can identify and quantify proglucagon-derived peptides in cells and tissues, revealing processing intermediates and mature products. These methods are essential for validating processing patterns in knockout or mutant models.
Secretion assays
Glucagon secretion from alpha cells can be measured using ELISA or radioimmunoassay after stimulation with low glucose or other secretagogues. These assays link processing to functional hormone release.
CRISPR-based gene editing
CRISPR knockout, point mutation, and knock-in models allow precise dissection of genes involved in glucagon processing, such as PCSK1, PCSK2, and CPE. These models can be used in immortalized alpha cell lines or primary islets.
Bioinformatics and pathway analysis
Transcriptomic and genomic data can be analyzed to identify regulators of GCG expression and processing enzymes. Bioinformatics tools help integrate multi-omics data to understand the regulatory network.
How CRISPR Can Be Used to Study GO:0120116 glucagon processing
Knockout
CRISPR knockout of genes such as PCSK2, PCSK1, or CPE in alpha cell lines can abolish or alter glucagon processing, providing direct evidence of their roles. Knockout models are also used to study the consequences of processing defects on secretion and glucose homeostasis.
Point Mutation
Introducing specific point mutations in GCG or processing enzyme genes can mimic human variants and reveal their impact on cleavage efficiency and hormone function. This approach helps distinguish pathogenic mutations from benign polymorphisms.
Knock-in
Knock-in of tagged proglucagon (e.g., with GFP) allows real-time tracking of processing and trafficking in live cells. Knock-in of human disease variants into mouse models can recapitulate processing defects.
Overexpression
Overexpression of processing enzymes or proglucagon can enhance or saturate the processing pathway, helping to define rate-limiting steps. This is useful for biochemical studies and for producing recombinant peptides.
How EDITGENE Supports glucagon processing Research
Researchers studying glucagon processing-related genes often need to determine whether a candidate gene is causally involved in proglucagon cleavage, secretion, or metabolic regulation. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for glucagon processing research.
Frequently Asked Questions About glucagon processing
What is glucagon processing?
Glucagon processing (GO:0120116) is the biological process in which the precursor proglucagon is proteolytically cleaved to form mature glucagon.
What genes are involved in glucagon processing?
Key genes include GCG (encoding proglucagon), PCSK1, PCSK2, and CPE, which encode the processing enzymes.
Where does glucagon processing occur?
It occurs primarily in pancreatic alpha cells, and related processing occurs in intestinal L cells.
What enzymes cleave proglucagon?
Prohormone convertases PC1/3 and PC2, along with carboxypeptidase E, are the main enzymes.
How is glucagon processing regulated?
It is regulated by transcription factors, convertase expression, and metabolic signals such as glucose.
What diseases are linked to glucagon processing?
Diabetes, glucagonomas, and glucagon deficiency states are associated with defects in processing or secretion.
Can CRISPR be used to study glucagon processing?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools for dissecting the process.
What is proglucagon?
Proglucagon is the precursor protein encoded by GCG that is processed into glucagon and other peptides.
How is mature glucagon formed?
Mature glucagon is formed by endoproteolytic cleavage by PC2 followed by exoproteolytic trimming by CPE.
What is miniglucagon?
Miniglucagon is a smaller peptide produced by extracellular cleavage of glucagon, with distinct biological activities.
Conclusion
Glucagon processing (GO:0120116) is a fundamental biological process that generates the hormone glucagon from its precursor proglucagon through the coordinated action of prohormone convertases and carboxypeptidase E. Its correct regulation is essential for glucose homeostasis, and its dysregulation is implicated in diabetes and related metabolic disorders. Advances in CRISPR gene editing and analytical technologies continue to illuminate the molecular details of this pathway, offering opportunities for therapeutic intervention.
References
- 1. Lund A et al.. 2019. Extrapancreatic glucagon: Present status.. Diabetes Res Clin Pract 147:19-28 PMID: 29944966
- 2. Blache P et al.. 1994. Miniglucagon production from glucagon: an extracellular processing of a hormone used as a prohormone.. Biochimie 76(3-4):295-9 PMID: 7819338
- 3. Gylfe E et al.. 2014. Glucose regulation of glucagon secretion.. Diabetes Res Clin Pract 103(1):1-10 PMID: 24367972
- 4. Wewer Albrechtsen NJ et al.. 2016. Do glucagonomas always produce glucagon?. Bosn J Basic Med Sci 16(1):1-7 PMID: 26773171
- 5. Lafferty RA et al.. 2021. Proglucagon-Derived Peptides as Therapeutics.. Front Endocrinol (Lausanne) 12:689678 PMID: 34093449
- 6. Briant L et al.. 2016. Glucagon secretion from pancreatic α-cells.. Ups J Med Sci 121(2):113-9 PMID: 27044683
- 7. Drucker DJ. 1990. Glucagon and the glucagon-like peptides.. Pancreas 5(4):484-8 PMID: 2199968
- 8. Hayashi Y. 2011. Metabolic impact of glucagon deficiency.. Diabetes Obes Metab 13 Suppl 1:151-7 PMID: 21824269
